BRAF V600E mutant colorectal cancer subtypes based on gene expression

Clinical Cancer Research

Volumn 23, Issue 1, 2017, Pages 104-115

  Barras, David ^a   Missiaglia, Edoardo ^a   Wirapati, Pratyaksha ^a   Sieber, Oliver M ^b,c   Jorissen, Robert N ^b,c   Love, Chris ^b,c   Molloy, Peter L ^d   Jones, Ian T ^c   McLaughlin, Stephen ^e   Gibbs, Peter ^b,c,f   Guinney, Justin ^g   Simon, Iris M ^h   Roth, Arnaud D ⁱ   Bosman, Fred T ^j   Tejpar, Sabine ^k,l   Delorenzi, Mauro ^a,j,m  

^a SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CSIRO   (Australia)

^e WESTERN HOSPITAL   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g SAGE BIONETWORKS   (United States)

^h Agendia NV   (Netherlands)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j UNIVERSITY OF LAUSANNE   (Switzerland)

^k UNIVERSITY OF LEUVEN   (Belgium)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m UNIVERSITY OF LAUSANNE   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; INITIATION FACTOR 4E BINDING PROTEIN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VALINE; TUMOR MARKER;

ARTICLE; BRAF GENE; CELL CYCLE REGULATION; COHORT ANALYSIS; COLORECTAL CANCER; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENDER; GENE CLUSTER; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; MICROSATELLITE INSTABILITY; ONCOGENE; PROTEIN PHOSPHORYLATION; PROTEOMICS; UPREGULATION; AMINO ACID SUBSTITUTION; BIOLOGICAL MODEL; BIOLOGY; CANCER STAGING; CLUSTER ANALYSIS; CODON; COLORECTAL TUMOR; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MORTALITY; MUTATION; PROCEDURES; PROGNOSIS; SIGNAL TRANSDUCTION; WORKFLOW;

AMINO ACID SUBSTITUTION; BIOMARKERS, TUMOR; CLUSTER ANALYSIS; CODON; COHORT STUDIES; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; DNA METHYLATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MODELS, BIOLOGICAL; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTEOMICS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; WORKFLOW;

EID: 85010403676     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0140     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
3. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-90.
4. Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M, et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 2013;62:540-9.
5. Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 2012;30:1288-95.
6. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
7. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015;33:4032-8.
8. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013;14:749-59.
9. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010;28:15s, (suppl; abstr 3534).
10. De RW, Claes B, Bernasconi D, De SJ, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
11. Yaeger R, Cercek A, O'Reilly EM, Reidy DL, Kemeny N, Wolinsky T, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 2015;21:1313-20.
12. Corcoran RB, Falchook GS, Infante JR, Hamid O, Messersmith WA, Daud A, et al. Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC). J Clin Oncol 2013;31: (suppl; abstr 3507).
13. Atreya CE, Van Cutsem E, Bendell JC, Andre T, Schellens JHM, Gordon MS, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol 2015;33(suppl; abstr 103).
14. Elez E, Kocakova I, Hohler T, Martens UM, Bokemeyer C, Van CE, et al. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol 2015;26:132-40.
15. Hong DS, Morris V, Fu S, Overman MJ, Piha-Paul SA, Kee BK, et al. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 2014;32:5s: (suppl; abstr 3516).
16. http://cancer.sanger.ac.uk/cosmic
17. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
18. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21.
19. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900.
20. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013;105:1151-6.
21. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
22. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013;231:63-76.
23. De Sousa E Melo, Wang X, Jansen M, Fessler E, Trinh A, De Rooij LP, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013;19:614-8.
24. Marisa L, De RA, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013;10:e1001453.
25. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez-Campos G, Calles A, Lopez-Asenjo JA, et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 2012;12:260.
26. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer 2014;134:552-62.
27. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013;19:619-25.
28. Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 2012;5:66.
29. Guinney J, Dienstmann R, Wang X, De RA, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350-6.
30. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012;104:1635-46.
31. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29:17-24.
32. http://bcf.isb-sib.ch/Projects/CRC-BRAFmut-subtypes.html
33. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118-27.
34. http://bcf.isb-sib.ch/Resources.html
35. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:1-25.
36. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
37. http://cancer.sanger.ac.uk/cell-lines
38. Rousseeuw PJ. Silhouettes - A Graphical Aid to the Interpretation and Validation of Cluster-Analysis. J Comp Appl Math 1987;20:53-65.
39. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011;27:1739-40.
40. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
41. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18.
42. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015;12:453-7.
43. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, et al. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS ONE 2009;4:e8357.
44. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-93.
45. Saridaki Z, Souglakos J, Georgoulias V. Prognostic and predictive significance of MSI in stages II/III colon cancer. World J Gastroenterol 2014;20:6809-14.
46. Haghighat A, Mader S, Pause A, Sonenberg N. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J 1995;14:5701-9.
47. O'Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, et al. Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 2009;15:2872-8.
48. Prahallad A, Sun C, Huang S, Di NF, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
49. Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol 2015;16:281-98.
50. Rad R, Cadinanos J, Rad L, Varela I, Strong A, Kriegl L, et al. A genetic progression model of Braf (V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 2013;24:15-29.